Biotech’s powerhouses kept the FDA pipeline moving, but the sector’s smaller players faced a harsh reset. While major approvals rolled in, layoffs and program shutdowns hit hard elsewhere.
Roche, Novartis, Pfizer, and Eli Lilly each locked in new FDA clearances for therapies in cancer, immunology, and rare disease. Roche’s Tecentriq regimen, now approved for adjuvant use in Stage III mismatch repair-deficient colon cancer, cut recurrence or death risk by half in the Phase 3 ATOMIC trial. Novartis’ Rhapsido became the first FDA-sanctioned treatment for symptomatic dermographism. Pfizer’s TUKYSA picked up a new maintenance nod for HER2+ breast cancer, adding over eight months of median progression-free survival in the HER2CLIMB-05 study. Eli Lilly’s Jaypirca now holds first-line approval for chronic lymphocytic leukaemia or small lymphocytic lymphoma, standing alone as a non-covalent BTK inhibitor in this setting.
The FDA approved Tecentriq (atezolizumab) and its subcutaneous form Tecentriq Hybreza for adjuvant treatment of patients as young as 2 years old with stage III dMMR colon cancer, based on the ATOMIC/ML39057 study.
But optimism faded fast for others. Caribou Biosciences pulled the plug on two allogeneic CAR-T programs—vispa-cel for B-cell non-Hodgkin lymphoma and CB-011 for multiple myeloma—and announced job cuts, blaming sector-wide financing pressure. The company is now weighing options, including a sale or merger. Foghorn Therapeutics followed, planning to cut 40% of its staff to stretch cash into 2029 and double down on core pipeline work.
Deals and Strategic Shifts
Deal flow stayed active. GE HealthCare agreed to buy SOFIE Biosciences for $945 million, aiming to grow its U.S. radiopharmaceutical reach. Alvotech signed a long-term manufacturing deal with LOTTE Biologics to ramp up biosimilar output from New York. Halozyme and Argenx expanded their ENHANZE partnership, adding two new targets for subcutaneous immunology drugs. Nurix and Gilead extended their oncology research tie-up, with Nurix banking a $10 million extension fee and keeping co-development rights on select programs.
CSL and Alentis Therapeutics inked a global pact to co-develop lixudebart for ANCA-associated vasculitis and other kidney and liver diseases, with the deal valued up to $1.6 billion. Myriad Genetics and SOPHiA GENETICS joined AstraZeneca to push forward a new prostate cancer genomic instability biomarker, PrGIS, aiming to sharpen patient selection for precision oncology.
Caribou Biosciences reported that as of June 30, 2026, it held $113.8 million in cash, cash equivalents, and marketable securities. Following the discontinuation of its CAR-T programs, the company plans to retain a limited number of employees to oversee strategic processes and wind down operations.
Clinical Evidence and Pipeline Progress
Trial results brought both momentum and setbacks. Pharvaris’ deucrictibant XR slashed hereditary angioedema attack rates by 83% in a pivotal Phase 3 study. Capricor’s Deramiocel slowed upper limb decline in Duchenne muscular dystrophy, with a 76% drop in decline rate for patients switching from placebo. BridgeBio’s BBP-418 normalized cardiac injury biomarkers in all treated patients with limb-girdle muscular dystrophy type 2I/R9 at 12 months, compared to 40% in the placebo arm.
Vaxcyte’s VAX-31 vaccine hit all primary endpoints in the Phase 3 OPUS-1 trial, showing non-inferior and, for some serotypes, superior immune responses versus licensed pneumococcal vaccines. The company is targeting a U.S. biologics license application in 2028. Argenx saw mixed results: its anti-CD122 antibody FB102 met the primary endpoint in celiac disease, but the Phase 3 UNITY trial of efgartigimod SC in Sjögren’s disease was stopped for futility.
Cell therapy volatility continues to echo trends seen in earlier coverage of CAR-T programs facing both clinical promise and commercial friction.
Regulatory and Market Implications
The FDA also cleared HeartSciences’ MyoVista wavECG device and TELA Bio’s fully resorbable Liora Scaffold, adding new tools for diagnostics and surgery. Lupin’s generic vitamin K injection and Lipocine’s TLANDO testosterone therapy won regulatory approval in the U.S. and Canada, expanding access to established treatments.
Large-cap players with strong pipelines and regulatory momentum are tightening their grip, while smaller firms are forced into layoffs or strategic pivots. The sector’s ability to turn clinical data into regulatory and commercial wins now hinges on navigating unforgiving biotech funding and competition. The last word this week belongs to the numbers, not the narrative.
